Your Sorted CME/CE Activities

New and Emerging Therapies for Rheumatoid Arthritis: Focus on Jakinibs - Updated 10/15/19
Certified CME/CNE/CPE Activity - Lecture Library Slide Set
Although stringent remission, or at least low disease activity, is the primary goal of RA therapy, many patients do not reach this target. The pathogenesis of RA non-responders remains unidentified and more research is needed to tie the epigenetic, environmental, and therapeutic factors together to optimize treatment response. To this end, development of new therapeutic approaches is an active area of research.

This activity will discuss potential drug targets, clinical needs/limitations of current RA therapy, data of new agents in late-stage clinical development, and the potential impact of new drugs on future management of RA patients.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review the slides by selecting the View Slide Kit button on the right. Claim 1 AMA, ANCC, or ACPE credit/contact hour per slide kit after completion of a brief posttest/evaluation.
Arthur Kavanaugh, MD
Arthur Kavanaugh, MD
Professor of Medicine
University of California at San Diego
Director, Center for Innovative Therapy
Division of Rheumatology, Allergy, and Immunology







20
Supported by an independent educational grant from Gilead Sciences Medical Affairs
June 30, 2020
Mini Module
6421
SSLectureLibrary_WebBanner_RA1150.gif
Rheumatology